Clinical Trials Browser

Phase 1/2 × Interventional × lorlatinib × Clear all

NCT06007937 2026-04-08

A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer

Phase 1/2 Recruiting

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Recurrence

NCT01970865 2024-08-12

A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations

Phase 1/2 Completed

364 enrolled 89 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT02584634 2023-07-07

Javelin Lung 101

Phase 1/2 Terminated

43 enrolled 40 charts

Carcinoma, Non-Small-Cell Lung

NCT04292119 2021-03-10

Lorlatinib Combinations in Lung Cancer

Phase 1/2 Unknown

Lung Neoplasms, Recurrence